Dolan Oliver 4

What Happened
Dolan Oliver, Senior Vice President, Finance at Korro Bio, received a grant/award of 15,000 derivative shares (reported as a $0.00 price) on February 2, 2026. The Form 4 reports this as an award/acquisition (code A) of a derivative security—i.e., an option-type award—rather than an open-market purchase or sale. No immediate sale or cash proceeds are associated with this transaction.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 3, 2026 (Accession 0001193125-26-035541).
• Transaction type: Award/Grant (derivative security, code A).
• Shares/units granted: 15,000; reported price: $0.00.
• Vesting: 48 equal monthly installments beginning February 2, 2026 (footnote F1). Continued service is required for each vesting date.
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: Reported the next day (no late-filing flag indicated).

Context
This is a compensation award with a multi-year vesting schedule—common for executive retention and incentive plans. It does not reflect an immediate market buy or sell; value to the insider depends on future vesting and any exercise/sale decisions. Retail investors should view this as a standard equity-compensation grant rather than an immediate insider market signal.